Ausgabe 9/2018
Inhalt (16 Artikel)
Targeting tumor-associated acidity in cancer immunotherapy
Ruben Lacroix, Elisa A. Rozeman, Marina Kreutz, Kathrin Renner, Christian U. Blank
Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab
Carlo Putzu, Diego Luigi Cortinovis, Francesca Colonese, Stefania Canova, Ciriaco Carru, Angelo Zinellu, Panagiotis Paliogiannis
mTOR-mediated glycolysis contributes to the enhanced suppressive function of murine tumor-infiltrating monocytic myeloid-derived suppressor cells
Yuting Deng, Jiao Yang, Feifei Luo, Jing Qian, Ronghua Liu, Dan Zhang, Hongxiu Yu, Yiwei Chu
Peripheral monocytes and neutrophils predict response to immune checkpoint inhibitors in patients with metastatic non-small cell lung cancer
Kaushal Parikh, Arun Kumar, Jibran Ahmed, Asad Anwar, Carmelo Puccio, Hoo Chun, Michael Fanucchi, Seah H. Lim
Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette–Guerin for patients with non-muscle invasive bladder cancer
Wataru Obara, Isao Hara, Yoichiro Kato, Renpei Kato, Keiji Inoue, Fuminori Sato, Hiromitsu Mimata, Yusuke Nakamura, Tomoaki Fujioka
Potentiation of PD-L1 blockade with a potency-matched dual cytokine–antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains
Roberto De Luca, Dario Neri
Levels of peripheral blood polymorphonuclear myeloid-derived suppressor cells and selected cytokines are potentially prognostic of disease progression for patients with non-small cell lung cancer
Lourdes Barrera, Edgar Montes-Servín, Juan-Manuel Hernandez-Martinez, Mario Orozco-Morales, Elizabeth Montes-Servín, David Michel-Tello, Renato Augusto Morales-Flores, Diana Flores-Estrada, Oscar Arrieta
Anti-ADAM17 monoclonal antibody MEDI3622 increases IFNγ production by human NK cells in the presence of antibody-bound tumor cells
Hemant K. Mishra, Nabendu Pore, Emil F. Michelotti, Bruce Walcheck
Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC
Nobuko Matsuura, Genju Koh, Chihiro Konishi, Satoshi Minamino, Yoshinori Takahara, Hiromasa Harada, Ken Kodama, Masanori Emoto
Naturally produced type I IFNs enhance human myeloid dendritic cell maturation and IL-12p70 production and mediate elevated effector functions in innate and adaptive immune cells
Annette E. Sköld, Till S. M. Mathan, Jasper J. P. van Beek, Georgina Flórez-Grau, Michelle D. van den Beukel, Simone P. Sittig, Florian Wimmers, Ghaith Bakdash, Gerty Schreibelt, I. Jolanda M. de Vries
Production of a mouse monoclonal IgM antibody that targets the carbohydrate Thomsen-nouveau cancer antigen resulting in in vivo and in vitro tumor killing
Kevin R. Trabbic, Kristopher A. Kleski, Mengchao Shi, Jean-Paul Bourgault, Jillian M. Prendergast, Daniel T. Dransfield, Peter R. Andreana
CD11c+ MHCIIlo GM-CSF-bone marrow-derived dendritic cells act as antigen donor cells and as antigen presenting cells in neoepitope-elicited tumor immunity against a mouse fibrosarcoma
Hakimeh Ebrahimi-Nik, William L. Corwin, Tatiana Shcheglova, Alok Das Mohapatra, Ion I. Mandoiu, Pramod K. Srivastava
Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma
Tessa Gargett, M. Nazim Abbas, Paul Rolan, Jason D. Price, Katharine M. Gosling, Antonio Ferrante, Andrew Ruszkiewicz, Ines I. C. Atmosukarto, Joseph Altin, Christopher R. Parish, Michael P. Brown
Reply to “Pseudoprogression”: more than semantics
Alvin S. Wong, Martin B. Lee
Correction to: High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer
Yusuke Okuma, Tsunekazu Hishima, Jumpei Kashima, Sadamu Homma